Palo Alto Investors Q2 2026 Portfolio Changes: Major Buys and Minor Sells in Biotech Focus

As of June 30th, 2026, Palo Alto Investors LP has maintained a concentrated portfolio primarily within the Healthcare sector. The fund's total value stands at $617,203,883.

Prominent Purchases This Quarter

The most significant buying activity by Palo Alto Investors LP during Q2 2026 appears to be focused on two key stocks: ACADIA PHARMACEUTICALS (ACHC) and COMPASS THERAPEUTICS (CMPX).

• ACADIA PHARMACEUTICALS (ACHC): This position saw a dramatic increase, with the fund acquiring an additional 2,864,096 shares. This represents a portfolio weight jump from presumably less than 10% to exactly 10.01%, indicating a substantial allocation increase.
• COMPASS THERAPEUTICS (CMPX): The fund also made a notable purchase, adding 431,730 shares to this position. This resulted in the stock's portfolio weight increasing from likely less than 1% (based on prior period implied value) to a current allocation of 1.76%.

Furthermore, the investor initiated new positions or significantly increased existing minor holdings in SAGIMET BIOSCIENCES-A (SGMT), NUVATION BIO (NUVB), PYXIS ONCOLOGY (PYXS), CELLDEX THERAPEUTICS (CLDX), VERASTEM (VSTM), and NEWAMSTERDAM PHARMA CO NV (NAMSW). These additions, while smaller in portfolio weight (0.27%, 0.26%, etc.), signal continued interest in the biotech space.

Significant Reductions and Exits

The portfolio also reflects notable reductions or exits from certain holdings:

• IOVANCE BIOTHERAPEUTICS (IOVA): The fund sold a substantial portion of its position, reducing the portfolio allocation by 16.59% to 3.04%. This significant decrease warrants attention.
• TRAVERE THERAPEUTICS (TVTX): The fund completely exited this position, removing it from the top holdings list despite its previous allocation of 1.32%. This exit might indicate a shift in strategic focus.
• PYXIS ONCOLOGY (PYXS): A moderate sale occurred, reducing the portfolio weight by 14.47% to 0.36%.
• PTC THERAPEUTICS (PTCT): A slight reduction was noted, decreasing the allocation by 0.3% to remain at 10.36%.

These actions suggest a dynamic approach where large gains are reinvested into promising new opportunities, while some established positions see reduced emphasis or complete divestment.

Ongoing Positions and Stability

The fund continues to hold several major Healthcare stocks:

• ANAPTYSBIO (ANAB): The allocation remained relatively stable at 5.63%.
• BIOMARIN PHARMACEUTICAL (DYN): Despite a small share reduction, the portfolio weight stayed constant at 5.06%.
• BIOGEN (BIIB): The allocation held steady at 4.19%.
• DISC MEDICINE (IRON): This position also maintained its portfolio weight despite share increases.